Novartis says 'non': Transgene becomes first megadeal casualty
This article was originally published in Scrip
Executive Summary
Novartis has decided it will not be exercising its option for Transgene's targeted cancer immunotherapy TG4010 MUC1 which is in Phase II development for non-small cell lung cancer (NSCLC).